Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hepatitis

  Free Subscription


Articles published in J Med Virol

Retrieve available abstracts of 166 articles:
HTML format



Single Articles


    June 2024
  1. LI X, Sun X, Pinpin J, Zhao Q, et al
    Multifunctional ORF3 protein of hepatitis E virus.
    J Med Virol. 2024;96:e29691.
    PubMed     Abstract available


  2. WEN X, Wu X, Sun Y, Zhou J, et al
    Long-term antiviral therapy is associated with changes in the profile of transcriptionally active HBV integration in the livers of patients with CHB.
    J Med Virol. 2024;96:e29606.
    PubMed     Abstract available


  3. FIGUEROA GB, D'souza S, Pereira HS, Vasudeva G, et al
    Development of a single-domain antibody to target a G-quadruplex located on the hepatitis B virus covalently closed circular DNA genome.
    J Med Virol. 2024;96:e29692.
    PubMed     Abstract available


  4. ZHENG D, Cheng C, Tang Y, Fang Z, et al
    Circulating metabolites are associated with persistent elevations of ALT in patients with chronic hepatitis B with complete viral suppression.
    J Med Virol. 2024;96:e29723.
    PubMed     Abstract available


  5. SCHEMMERER M, Bock HH, Schattenberg JM, Huber S, et al
    Proof of infectivity of hepatitis E virus particles from the ejaculate of chronically infected patients.
    J Med Virol. 2024;96:e29735.
    PubMed     Abstract available


    May 2024
  6. WU L, Deng H, Feng X, Xie D, et al
    Interferon-gamma(+) Th1 activates intrahepatic resident memory T cells to promote HBsAg loss by inducing M1 macrophage polarization.
    J Med Virol. 2024;96:e29627.
    PubMed     Abstract available


  7. PIRALLA A, Giardina F, Ferrari G, Gaiarsa S, et al
    Molecular characterization of emerging Echovirus 11 (E11) shed light on the recombinant origin of a variant associated with severe hepatitis in neonates.
    J Med Virol. 2024;96:e29658.
    PubMed     Abstract available


  8. LIANG Y, Zhang J, Luo D, Cheng L, et al
    Deregulation of immune response contributing to fulminant hepatitis in HEV infected pregnant women.
    J Med Virol. 2024;96:e29639.
    PubMed     Abstract available


  9. LI Q, Wen W, Wang Y, Gong T, et al
    Autophagy-related protein 5 (ATG5) interacts with bone marrow stromal cell antigen 2 (BST2) to stimulate HBV replication through antagonizing the antiviral activity of BST2.
    J Med Virol. 2024;96:e29659.
    PubMed     Abstract available


  10. LIU CH, Chang YP, Lee JY, Chen CY, et al
    Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals.
    J Med Virol. 2024;96:e29675.
    PubMed     Abstract available


  11. TAN A, He Y, Zhou Y, Peng X, et al
    A potential antiviral role for CCR5+CD8+ T cells in children with hepatitis B.
    J Med Virol. 2024;96:e29661.
    PubMed     Abstract available


  12. LAI X, OuYang W, Li S, Qiu J, et al
    Predictive role of early treatment dynamics of HBV RNA and HBcrAg for HBeAg seroconversion in children with chronic hepatitis B.
    J Med Virol. 2024;96:e29670.
    PubMed     Abstract available


  13. REN F, Zhao S, He X, Lo H, et al
    Discovery and mechanistic study of Imperatorin that inhibits HBsAg expression and cccDNA transcription.
    J Med Virol. 2024;96:e29669.
    PubMed     Abstract available


  14. CHANG YP, Huang CB, Su TH, Liu CJ, et al
    Comparison of diagnostic performance among Abbott RealTime HCV Genotyping II, Abbott HCV Genotype plus RUO, and Roche Cobas HCV Genotyping assays for hepatitis C virus genotyping.
    J Med Virol. 2024;96:e29686.
    PubMed     Abstract available


    April 2024
  15. ZHANG Y, Yuan X, Wang J, Han M, et al
    TRPV4 promotes HBV replication and capsid assembly via methylation modification of H3K4 and HBc ubiquitin.
    J Med Virol. 2024;96:e29510.
    PubMed     Abstract available



  16. Retraction: "Small Interfering RNA Effectively Inhibits Protein Expression and Negative Strand RNA Synthesis From a Full-Length Hepatitis C Virus Clone".
    J Med Virol. 2024;96:e29574.
    PubMed     Abstract available


  17. JIANG B, Wang L, Liu H, Wang L, et al
    Association of HBV serological markers with host antiviral immune response relevant hepatic inflammatory damage in chronic HBV infection.
    J Med Virol. 2024;96:e29569.
    PubMed     Abstract available


  18. CHEN L, Tao X, Zeng M, Li Y, et al
    Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease.
    J Med Virol. 2024;96:e29613.
    PubMed     Abstract available


  19. HOU L, Zhao J, Cai L, Jin L, et al
    HBV PreC interacts with SUV39H1 to induce viral replication by blocking the proteasomal degradation of viral polymerase.
    J Med Virol. 2024;96:e29607.
    PubMed     Abstract available


    March 2024
  20. CHEN X, Dong S, Shi Y, Wu Z, et al
    Biosensor-based multiple cross displacement amplification platform for visual and rapid identification of hepatitis C virus.
    J Med Virol. 2024;96:e29481.
    PubMed     Abstract available


  21. WANG LT, Chen YH, Cheng Y, Fan HL, et al
    Clinical implications of hepatitis B virus core antigen-mediated immunopathologic T cell responses in chronic hepatitis B.
    J Med Virol. 2024;96:e29515.
    PubMed     Abstract available


  22. YANG J, Xu S, Cheng J, Yin X, et al
    CXCL10 and its receptor in patients with chronic hepatitis B and their ability to predict HBeAg seroconversion during antiviral treatment with TDF.
    J Med Virol. 2024;96:e29516.
    PubMed     Abstract available


  23. CHEN J, Shen L, Guo Q, Ma S, et al
    The downregulation of Tapasin in dendritic cell regulates CD8(+) T cell autophagy to hamper hepatitis B viral clearance in the induced pluripotent stem cell-derived hepatocyte organoid.
    J Med Virol. 2024;96:e29546.
    PubMed     Abstract available


  24. ZHA G, Chen Z, Wu N, Huang T, et al
    Clinical characteristics and immunogenicity after Omicron breakthrough infection in patients with chronic hepatitis B infection: A longitudinal observational study.
    J Med Virol. 2024;96:e29548.
    PubMed     Abstract available


  25. MIUMA S, Miyaaki H, Ichikawa T, Matsuzaki T, et al
    Non-liver-related mortality in the DAA era: Insights from post-SVR patients with and without previous HCC history.
    J Med Virol. 2024;96:e29432.
    PubMed     Abstract available


  26. ZHANG H, Li M, Liu H, Dong Y, et al
    Juveniles, young adults, and infants with hepatitis B virus infection: A genomic study.
    J Med Virol. 2024;96:e29530.
    PubMed     Abstract available


    February 2024
  27. GUO L, Liu JJ, Long SY, Wang PY, et al
    TIM22 and TIM29 inhibit HBV replication by up-regulating SRSF1 expression.
    J Med Virol. 2024;96:e29439.
    PubMed     Abstract available


  28. CHEN B, Xu B, Cui HY, Ma ZH, et al
    Comparison of effectiveness and cost of different HCV testing strategies in high-risk populations in China.
    J Med Virol. 2024;96:e29433.
    PubMed     Abstract available


  29. LU X, Li W, Deng R, Zhou B, et al
    Serum hepatitis B virus spliced RNA proportion increases with liver disease progression in patients with chronic hepatitis B.
    J Med Virol. 2024;96:e29400.
    PubMed     Abstract available


  30. LIU W, Li L, Yin M, Cao C, et al
    High-speed centrifugation rather than Lipoclear reagent can be used for removing the interference of lipemia on serological tests of infectious diseases: AIDS, hepatitis B, hepatitis C, and syphilis by chemiluminescent microparticle immunoassay.
    J Med Virol. 2024;96:e29385.
    PubMed     Abstract available


  31. BLANCO S, Castro GM, Sicilia PE, Carrizo LH, et al
    Breakthrough infection by hepatitis B virus in a vaccinated blood donor: An emerging threat for transfusion safety in low-endemic countries?
    J Med Virol. 2024;96:e29463.
    PubMed     Abstract available


  32. LIU Y, Kim ES, Guo H
    Hepatitis B virus-related hepatocellular carcinoma exhibits distinct intratumoral microbiota and immune microenvironment signatures.
    J Med Virol. 2024;96:e29485.
    PubMed     Abstract available


    January 2024
  33. SU YP, Lin SY, Su IJ, Kao YL, et al
    Characterization of integrated hepatitis B virus DNA harboring pre-S mutations in hepatocellular carcinoma patients with ground glass hepatocytes.
    J Med Virol. 2024;96:e29348.
    PubMed     Abstract available


  34. LI M, Wei Z, Su J, Wu X, et al
    Changing spectrum and mortality disparities of etiology of liver cirrhosis in Beijing, China.
    J Med Virol. 2024;96:e29405.
    PubMed     Abstract available


  35. ADHIKARI A, Abayasingam A, Brasher NA, Kim HN, et al
    Characterization of antibody-dependent cellular phagocytosis in patients infected with hepatitis C virus with different clinical outcomes.
    J Med Virol. 2024;96:e29381.
    PubMed     Abstract available


  36. PARK K, Kim J, Noh J, Kim K, et al
    First detection and characterization of hepatitis E virus (Rocahepevirus ratti) from urban Norway rats (Rattus norvegicus) in the Republic of Korea.
    J Med Virol. 2024;96:e29401.
    PubMed     Abstract available


  37. SHI J, Wang X, Qi W, Wang S, et al
    Association between NTCP hepatic expression and inflammation/fibrosis as well as gender-specific differences in chronic HBV-infected patients.
    J Med Virol. 2024;96:e29428.
    PubMed     Abstract available


    December 2023
  38. PI Y, Li Y, Yan Q, Luo H, et al
    SPOP inhibits HBV transcription and replication by ubiquitination and degradation of HNF1alpha.
    J Med Virol. 2023;95:e29254.
    PubMed     Abstract available


  39. ABDEL-SAMIEE M, Youssef MI, Elghamry F, Bazeed M, et al
    A multicentric and nationwide predictive study role of T cell sub-population in the prevalence and prognosis of cryoglobulinemia among genotype 4 chronic hepatitis C patients.
    J Med Virol. 2023;95:e29248.
    PubMed     Abstract available


  40. LIANG YJ, Chiou YW, Chiu AP, Shiao MS, et al
    Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR-122.
    J Med Virol. 2023;95:e29325.
    PubMed     Abstract available


  41. NGARI JW, Leumi S, Han L, Liu C, et al
    Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon.
    J Med Virol. 2023;95:e29290.
    PubMed     Abstract available


  42. NUERMAIMAITI A, Chang L, Yan Y, Sun H, et al
    The role of sex hormones and receptors in HBV infection and development of HBV-related HCC.
    J Med Virol. 2023;95:e29298.
    PubMed     Abstract available


    November 2023
  43. KRUMBHOLZ A, Marcic A, Valentin M, Schemmerer M, et al
    Hepatitis A outbreak in a refugee shelter in Kiel, northern Germany.
    J Med Virol. 2023;95:e29185.
    PubMed     Abstract available


  44. LI W, Zhang H, Ren A, Fan W, et al
    Systemic lupus erythematosus is associated with lower risk of hepatitis B virus infection: A multivariable Mendelian randomization study in East Asian population.
    J Med Virol. 2023;95:e29226.
    PubMed     Abstract available


  45. WANG C, Zhang S, Zhao J, Wang M, et al
    Changes and gaps of global and regional disease burden of hepatitis B infection in children younger than 5 years old between 2015 and 2019: A real-world data review.
    J Med Virol. 2023;95:e29241.
    PubMed     Abstract available


  46. LIM CK, Romeo O, Tran BM, Flanagan DJ, et al
    Assessment of hepatitis B virus infection and interhost cellular responses using intrahepatic cholangiocyte organoids.
    J Med Virol. 2023;95:e29232.
    PubMed     Abstract available


    October 2023
  47. FU MX, Simmonds P, Andreani J, Baklan H, et al
    Ultrasensitive PCR system for HBV DNA detection: Risk stratification for occult hepatitis B virus infection in English blood donors.
    J Med Virol. 2023;95:e29144.
    PubMed     Abstract available


  48. WU WJ, Lin CL, Liu CJ, Huang YW, et al
    Lifetime risk of liver-related outcomes and determinants in male inactive carriers of chronic hepatitis B.
    J Med Virol. 2023;95:e29138.
    PubMed     Abstract available


  49. LIU J, Zhang H, Kong J, Liu S, et al
    Alleviated symptoms of SARS-CoV-2 Omicron variant infection in chronic hepatitis B patients with immune control.
    J Med Virol. 2023;95:e29173.
    PubMed     Abstract available


  50. ZHANG M, Chen S, Wu X, Zhou J, et al
    Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection.
    J Med Virol. 2023;95:e29156.
    PubMed     Abstract available


  51. ZHAN Y, Tao Q, Lang Z, Lin L, et al
    Serum ribonucleotide reductase M2 is a potential biomarker for diagnosing and monitoring liver fibrosis in chronic hepatitis B patients.
    J Med Virol. 2023;95:e29157.
    PubMed     Abstract available


  52. ELIZALDE MM, Giadans CG, Campos RH, Flichman DM, et al
    Impact of core protein naturally selected mutants associated with HBeAg-negative status in HBV biosynthesis.
    J Med Virol. 2023;95:e29195.
    PubMed     Abstract available


  53. REN H, Chen X, Wang J, Chen Y, et al
    Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma.
    J Med Virol. 2023;95:e29187.
    PubMed     Abstract available


  54. YANG D, Zou J, Guan G, Feng X, et al
    The A1762T/G1764A mutations enhance HBV replication by alternating viral transcriptome.
    J Med Virol. 2023;95:e29129.
    PubMed     Abstract available


  55. TANG L, Li Q, Chen L, Li X, et al
    IL-21 collaborates with anti-TIGIT to restore NK cell function in chronic HBV infection.
    J Med Virol. 2023;95:e29142.
    PubMed     Abstract available


    September 2023
  56. SHEN Z, Zhang S, Jiang Q, Liu N, et al
    Lipid nanoparticle-mediated delivery of IL-21-encoding mRNA induces viral clearance in mouse models of hepatitis B virus persistence.
    J Med Virol. 2023;95:e29062.
    PubMed     Abstract available


  57. PENG X, Shi Y, Zhang B, Xu C, et al
    Establishment of nucleic acid sensing pathways-based model in predicting response to immunotherapy and targeted drug in hepatitis virus-related hepatocellular carcinoma.
    J Med Virol. 2023;95:e29084.
    PubMed     Abstract available


  58. SUZUKI T, Matsuura K, Watanabe T, Matsui T, et al
    Kinetics of HBcrAg and HBsAg using highly sensitive iTACT assays in chronic hepatitis B patients with HBsAg seroclearance.
    J Med Virol. 2023;95:e29109.
    PubMed     Abstract available


  59. LIU C, Guo M, Han L, Lu J, et al
    Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.
    J Med Virol. 2023;95:e29103.
    PubMed     Abstract available


    August 2023
  60. GUO M, Zhao L, Jiang C, Jia CC, et al
    Multiomics analyses reveal pathological mechanisms of HBV infection and integration in liver cancer.
    J Med Virol. 2023;95:e28980.
    PubMed     Abstract available


  61. ZENG DY, Chen Z, Hong MZ, Jiang LP, et al
    Traditional Chinese medicine invigorating the spleen and kidney promotes HBsAg seroclearance in the mouse model.
    J Med Virol. 2023;95:e28979.
    PubMed     Abstract available


  62. ROY A, Saade C, Josset L, Clement B, et al
    Determinants of protection against SARS-CoV-2 Omicron BA.1 and Delta infections in fully vaccinated outpatients.
    J Med Virol. 2023;95:e28984.
    PubMed     Abstract available


  63. LIM CK, Tran BM, Flanagan D, McCartney E, et al
    Assessment of HBV infection and inter-host cellular responses using intrahepatic cholangiocyte organoids.
    J Med Virol. 2023;95:e28975.
    PubMed     Abstract available


  64. YE X, Li T, Yu B, Zeng J, et al
    The high prevalence of occult hepatitis B infections among the partners of chronically infected HBV blood donors emphasizes the potential residual risk to blood safety.
    J Med Virol. 2023;95:e29006.
    PubMed     Abstract available


  65. ADACHI E, Saito M, Kikuchi T, Ikeuchi K, et al
    Incidence of sexually transmitted hepatitis C virus infection among men who have sex with men in Japan from 2009 to 2023.
    J Med Virol. 2023;95:e29039.
    PubMed     Abstract available


    July 2023
  66. GATES S, Andreani J, Dewar R, Smith DB, et al
    Postpandemic rebound of adeno-associated virus type 2 (AAV2) infections temporally associated with an outbreak of unexplained severe acute hepatitis in children in the United Kingdom.
    J Med Virol. 2023;95:e28921.
    PubMed     Abstract available


  67. HOGAN G, Winer BY, Ahodantin J, Sellau J, et al
    Persistent hepatitis B virus and HIV coinfections in dually humanized mice engrafted with human liver and immune system.
    J Med Virol. 2023;95:e28930.
    PubMed     Abstract available


  68. KANG NL, Gao YH, Lin MX, Wu LY, et al
    Development a novel nomogram model for predicting significant hepatic histological changes in chronic hepatitis B virus carriers.
    J Med Virol. 2023;95:e28943.
    PubMed     Abstract available


  69. LUO M, Zhang L, Yang C, Zhou B, et al
    CXCL13 variant predicts pegylated-interferon alpha treatment response in HBeAg-positive chronic hepatitis B patients.
    J Med Virol. 2023;95:e28963.
    PubMed     Abstract available


  70. ZHAO L, Yuan H, Wang Y, Geng Y, et al
    HBV confers innate immune evasion through triggering HAT1/acetylation of H4K5/H4K12/miR-181a-5p or KPNA2/cGAS-STING/IFN-I signaling.
    J Med Virol. 2023;95:e28966.
    PubMed     Abstract available


  71. LARA-AGUILAR V, Crespo-Bermejo C, Llamas-Adan M, Grande-Garcia S, et al
    HCV spontaneous clearers showed low senescence profile in people living with HIV under long ART.
    J Med Virol. 2023;95:e28955.
    PubMed     Abstract available


  72. ZHANG J, Zhang Y, Khanal S, Cao D, et al
    Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
    J Med Virol. 2023;95:e28952.
    PubMed     Abstract available


  73. YAO YX, Chen Y, Huang D, Liu C, et al
    RNA-binding motif protein 24 inhibits HBV replication in vivo.
    J Med Virol. 2023;95:e28969.
    PubMed     Abstract available


    June 2023
  74. LI J, Li J, Chen S, Xu W, et al
    Clinical isolates of hepatitis B virus genotype C have higher in vitro transmission efficiency than genotype B isolates.
    J Med Virol. 2023;95:e28879.
    PubMed     Abstract available


  75. SHI L, Wang Y, Cao X, Huang W, et al
    Increasing positive rate of IgG against hepatitis E virus with steady IgM positivity and clinical incidence: A retrospective seroprevalence time series analysis of HEV from 2012 to 2021 in Chongqing, China.
    J Med Virol. 2023;95:e28872.
    PubMed     Abstract available


  76. SUGIYAMA R, Takahara O, Yahata Y, Kanou K, et al
    Nationwide epidemiologic and genetic surveillance of hepatitis E in Japan, 2014-2021.
    J Med Virol. 2023;95:e28886.
    PubMed     Abstract available


  77. ZHENG L, Wang L, Lu F
    Looking back on the outbreak of acute severe hepatitis with unknown etiology in children in 2022: What do we know now and where do we go from here?
    J Med Virol. 2023;95:e28890.
    PubMed    


    April 2023
  78. XIE Z, Shen S, Huang K, Wang W, et al
    Mitochondrial HIGD1A inhibits hepatitis B virus transcription and replication through the cellular PNKD-NF-kappaB-NR2F1 nexus.
    J Med Virol. 2023;95:e28749.
    PubMed     Abstract available


  79. HE L, Cai Q, Liang X, Xin J, et al
    ETS2 alleviates acute-on-chronic liver failure by suppressing excessive inflammation.
    J Med Virol. 2023;95:e28710.
    PubMed     Abstract available


    March 2023
  80. CHEN Z, Huang T, He T, Zha G, et al
    Humoral responses after primary and booster SARS-CoV-2 inactivated vaccination in patients with chronic hepatitis B virus infection: a longitudinal observational study.
    J Med Virol. 2023 Mar 22. doi: 10.1002/jmv.28695.
    PubMed     Abstract available


  81. WU B, Tobe RG, Yan M, Lin H, et al
    Trends of Global Burden Related to HBV and HCV from 1990 to 2019: An Age-Period-Cohort Analysis.
    J Med Virol. 2023 Mar 11. doi: 10.1002/jmv.28663.
    PubMed     Abstract available


  82. LIU Y, Chen M
    Is nonalcoholic fatty liver disease a predictor of treatment response in chronic hepatitis B?
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28654.
    PubMed     Abstract available


  83. XU W, Zhu S, Yang L, Li Z, et al
    Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28650.
    PubMed     Abstract available


  84. PISATURO M, Alessio L, Starace M, Macera M, et al
    CHARACTERIZATION OF HEPATITIS VIRUS CO-INFECTIONS IN A COHORT OF IMMIGRANTS LIVING IN SOUTHERN ITALY.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28665.
    PubMed     Abstract available


  85. GAO L, Gao Y, Han K, Wang Z, et al
    FBXO11 amplifies type I interferon signaling to exert antiviral effects by facilitating the assemble of TRAF3-TBK1-IRF3 complex.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28655.
    PubMed     Abstract available


  86. FENG Z, Huang P, Zhang J, Xia X, et al
    KIR2DL4/HLA-G polymorphisms were associated with HCV infection susceptibility among Chinese high-risk population.
    J Med Virol. 2023 Mar 8. doi: 10.1002/jmv.28645.
    PubMed     Abstract available


  87. CHARRE C, Regue H, Deny P, Josset L, et al
    Improved Hepatitis Delta Virus genome characterization by single molecule full-length genome sequencing combined with VIRiONT pipeline.
    J Med Virol. 2023 Mar 6. doi: 10.1002/jmv.28634.
    PubMed     Abstract available


  88. CAI T, Yue T, Xu M, Zhang P, et al
    Poor glycemic control in type-2 diabetic patients infected with hepatitis B: a retrospective propensity-matched study.
    J Med Virol. 2023 Mar 4. doi: 10.1002/jmv.28635.
    PubMed     Abstract available


  89. WANG Q, Liu Y, Luo J, Yang S, et al
    A systematic comparison reveals dynamic differences in early adaptive immune responses of acute-resolving versus chronic HBV replication.
    J Med Virol. 2023;95:e28670.
    PubMed     Abstract available


  90. REN F, Hu J, Dang Y, Deng H, et al
    Sphondin efficiently blocks HBsAg production and cccDNA transcription through promoting HBx degradation.
    J Med Virol. 2023;95:e28578.
    PubMed     Abstract available


    February 2023
  91. TU W, Liu J, Qian F, Zhu L, et al
    Ubiquitin E3 ligase beta-TrCP negatively regulates surface protein of hepatitis B virus.
    J Med Virol. 2023 Feb 27. doi: 10.1002/jmv.28620.
    PubMed     Abstract available


  92. LIAO H, Zhang H, Shao J, Li X, et al
    Nucleos(t)ide analogues altered quasispecies composition of hepatitis B virus (HBV)-resistant mutations in serum HBV DNA and serum HBV RNA.
    J Med Virol. 2023 Feb 25. doi: 10.1002/jmv.28612.
    PubMed     Abstract available


  93. KASHYAP N, Islam M, Kaur H, Tiwari D, et al
    Oxidative stress - a key determinant of complications and negative outcome in Hepatitis E virus infected pregnancies: a comprehensive account involving cases from northeast India.
    J Med Virol. 2023 Feb 13. doi: 10.1002/jmv.28576.
    PubMed     Abstract available


  94. SHUI LP, Zhu Y, Duan XQ, Chen YT, et al
    HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy.
    J Med Virol. 2023 Feb 3. doi: 10.1002/jmv.28549.
    PubMed     Abstract available


  95. NOT A, Saludes V, Galvez M, Miralpeix A, et al
    Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program.
    J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28544.
    PubMed     Abstract available


  96. CHEN S, Wang B, Zhou J, Wu X, et al
    A new glutamine synthetase index to evaluate hepatic lobular restoration in advanced fibrosis during anti-HBV therapy.
    J Med Virol. 2023;95:e28555.
    PubMed     Abstract available


    January 2023
  97. XIE J, Ding Y, Li X, Pu R, et al
    Association of ESR1 gene polymorphisms with the susceptibility to Hepatitis B virus infection and the clinical outcomes.
    J Med Virol. 2023 Jan 20. doi: 10.1002/jmv.28510.
    PubMed     Abstract available


  98. HASSEBROEK AM, Sooryanarain H, Lynn Heffron C, Hawks SA, et al
    A hepatitis B virus core antigen-based virus-like particle vaccine expressing SARS-CoV-2 B and T cell epitopes induces epitope-specific humoral and cell-mediated immune responses but confers limited protection against SARS-CoV-2 infection.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28503.
    PubMed     Abstract available


  99. TANG Y, Fan R, Lan Z, Xie Q, et al
    Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28501.
    PubMed     Abstract available


  100. SUDA G, Baba M, Yamamoto Y, Sho T, et al
    Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
    J Med Virol. 2023 Jan 4. doi: 10.1002/jmv.28452.
    PubMed     Abstract available


  101. XIANG Z, Jiang C, Yang J, Huang L, et al
    Serum extracellular vesicle-derived ASS1 is a promising predictor for the occurrence of HEV-ALF.
    J Med Virol. 2023;95:e28425.
    PubMed     Abstract available


  102. MOHAMED AA, Esmail OE, Ibrahim AMA, Makled S, et al
    The role of PRDM1 gene polymorphism in the progression of hepatocellular carcinoma in Egyptian patients.
    J Med Virol. 2023;95:e28343.
    PubMed     Abstract available


    December 2022
  103. KAR A, Samanta A, Mukherjee S, Barik S, et al
    The HBV web: An insight into molecular interactomes between the Hepatitis B virus and its host en route to hepatocellular carcinoma.
    J Med Virol. 2022 Dec 27. doi: 10.1002/jmv.28436.
    PubMed     Abstract available


  104. TUNCEL B, Kaygusuz S, Sayin Kocakap DB, Aksoy E, et al
    DO CCR5 (CCR5Delta32) AND TLR3 (RS5743313) GENE POLYMOPHISMS PREVENT CHRONIC HEPATITIS B INFECTION?
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28376.
    PubMed     Abstract available


    November 2022
  105. ARANDHARA VL, Patrick McClure C, Tarr AW, Chappell S, et al
    SCAVENGER RECEPTOR CLASS B TYPE I GENETIC VARIANTS ASSOCIATED WITH DISEASE SEVERITY IN CHRONIC HEPATITIS C VIRUS INFECTION.
    J Med Virol. 2022 Nov 22. doi: 10.1002/jmv.28331.
    PubMed     Abstract available


  106. CHEN J, Li F, Tian J, Xie X, et al
    Varicella Zoster Virus Reactivation Following COVID-19 Vaccination in patients with autoimmune inflammatory rheumatic diseases: A cross-sectional Chinese study of 318 cases.
    J Med Virol. 2022 Nov 13. doi: 10.1002/jmv.28307.
    PubMed     Abstract available


  107. SHI Y, Jin X, Wu S, Liu J, et al
    Release of hepatitis B virions is positively regulated by glucose-regulated protein 78 through direct interaction with preS1.
    J Med Virol. 2022 Nov 2. doi: 10.1002/jmv.28271.
    PubMed     Abstract available


    October 2022
  108. LUCIANI L, Bichon A, Mortier C, Bourenne J, et al
    Acute hepatitis associated with an echovirus 9 infection in a heart transplant recipient.
    J Med Virol. 2022 Oct 30. doi: 10.1002/jmv.28262.
    PubMed     Abstract available


  109. CHEN J, Yu S, Lang Z, Jin Y, et al
    Development and validation of a potential biomarker to improve the assessment of liver fibrosis progression in patients with chronic hepatitis B.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28239.
    PubMed     Abstract available


  110. KANEKO S, Kurosaki M, Mashiba T, Marusawa H, et al
    Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
    J Med Virol. 2022 Oct 12. doi: 10.1002/jmv.28210.
    PubMed     Abstract available


  111. ZHANG F, Yang Z, Dai C, He Q, et al
    Efficacy of an accelerated vaccination schedule against hepatitis E virus infection in pregnant rabbits.
    J Med Virol. 2022 Oct 6. doi: 10.1002/jmv.28193.
    PubMed     Abstract available


    September 2022
  112. LUO J, Liang X, Xin J, Li P, et al
    Serum ferritin diagnosis and prediction of hepatitis B virus-related acute-on-chronic liver failure.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28183.
    PubMed     Abstract available


  113. ADEBOYEJO K, King B, Tsoleridis T, Tarr A, et al
    Hepatitis C subtyping assay failure in UK patients born in Sub-Saharan Africa: implications for global treatment and elimination.
    J Med Virol. 2022 Sep 27. doi: 10.1002/jmv.28178.
    PubMed     Abstract available


  114. YU X, Zheng Y, Zeng D, Zhou Y, et al
    Decreased frequency of a novel T-lymphocyte subset, CD3(+) CD4(-) CD7(+) CD57(-) T cells, in hepatitis B virus-related end-stage liver disease might contribute to disease progression.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28129.
    PubMed     Abstract available


  115. CHALID MT, Turyadi, Ie SI, Sjahril R, et al
    A cautionary note to hepatitis B e antigen (HBeAg)-negative test results in pregnant women in an area prevalent of HBeAg-negative chronic hepatitis B.
    J Med Virol. 2022 Sep 5. doi: 10.1002/jmv.28125.
    PubMed     Abstract available


    August 2022
  116. PRICE AS, Nelson AK, Ghosh A, Kottilil S, et al
    A Phase 2 Open Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects with Hepatitis B Virus Infection.
    J Med Virol. 2022 Aug 31. doi: 10.1002/jmv.28105.
    PubMed     Abstract available


  117. CHEN Z, Yuan Y, Yang D, Luo M, et al
    Antiviral activities of Polygonum Perfoliatum L. extract and related phenolic acid constituents against hepatitis B virus.
    J Med Virol. 2022 Aug 24. doi: 10.1002/jmv.28087.
    PubMed     Abstract available


  118. MIYAZAWA D
    Potential mechanisms by which adeno-associated virus type 2 causes unexplained hepatitis in children.
    J Med Virol. 2022 Aug 22. doi: 10.1002/jmv.28082.
    PubMed     Abstract available


  119. SARFARAZ N, Somarowthu S, Bouchard MJ
    The Interplay of Long Non-Coding RNAs and Hepatitis B Virus.
    J Med Virol. 2022 Aug 9. doi: 10.1002/jmv.28058.
    PubMed     Abstract available


    July 2022
  120. RUPASINGHE D, Choi JY, Yunihastuti E, Kiertiburanakul S, et al
    Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-Pacific.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28019.
    PubMed     Abstract available


  121. CHEEMA HA, Shahid A, Aziz H
    Severe acute pediatric hepatitis: the undue emphasis on adenovirus needs to be reassessed.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28014.
    PubMed     Abstract available


  122. LIAN J, Kuang W, Jia H, Lu Y, et al
    Pegylated interferon-alpha-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naive HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomize
    J Med Virol. 2022 Jul 14. doi: 10.1002/jmv.28003.
    PubMed     Abstract available


  123. ZHANG Q, Liang J, Yin J, Jiang Y, et al
    Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose and uric acid in chronic hepatitis B patients.
    J Med Virol. 2022 Jul 6. doi: 10.1002/jmv.27977.
    PubMed     Abstract available


  124. RATHO RK, Thakur V, Arya S, Singh MP, et al
    Placenta as a site of HEV replication and inflammatory cytokines modulating the immunopathogenesis of HEV in pregnant women.
    J Med Virol. 2022;94:3457-3463.
    PubMed     Abstract available


    June 2022
  125. ZHONG S, Liu Z, Zhou Y, Zhang T, et al
    Longitudinal mapping of hepatitis B vaccine-induced B-cell linear epitopes in healthy individuals.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27926.
    PubMed     Abstract available


  126. ZHENG XQ, Li X, Liu J, Shi L, et al
    Horizontal transmission might be a common route of hepatitis B virus exposure in highly endemic areas.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27905.
    PubMed     Abstract available


  127. OHTA A, Ogawa E, Murata M, Matsumoto Y, et al
    Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27904.
    PubMed     Abstract available


    May 2022
  128. QI X, Li F, Zhang Y, Zhu H, et al
    STAT4 genetic polymorphism significantly affected HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving Peginterferon-alpha therapy: A prospective cohort study in China Running title: STAT4 variation affecting response to PegIF
    J Med Virol. 2022 May 24. doi: 10.1002/jmv.27880.
    PubMed     Abstract available


  129. ZENG QL, Yu ZJ, Lv J, Zhang HX, et al
    Sofosbuvir-based Therapy for Late Pregnant Women and Infant with Severe Chronic Hepatitis C: A Case Series Study.
    J Med Virol. 2022 May 20. doi: 10.1002/jmv.27877.
    PubMed     Abstract available


  130. LIANG LY, Yip TC, Lai JC, Lam AS, et al
    Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate.
    J Med Virol. 2022 May 17. doi: 10.1002/jmv.27863.
    PubMed     Abstract available


  131. HAKIM MS
    The recent outbreak of acute and severe hepatitis of unknown etiology in children: a possible role of human adenovirus infection?
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27856.
    PubMed     Abstract available


  132. XIE Z, Deng K, Xia Y, Zhang C, et al
    Efficacy and safety of direct-acting antiviral therapies and baseline predictors for treatment outcomes in hepatitis C patients: a multi-center, real-world study in Guangdong, China.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27851.
    PubMed     Abstract available


  133. MALONGA GA, Dienta S, Traore FT, Maiga Z, et al
    Human Herpesvirus 8 seroprevalence among blood donors in Mali.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27850.
    PubMed     Abstract available


  134. KOC OM, van Oorschot E, Brandts L, Lashof AO, et al
    Timing of primary three dose hepatitis B vaccination and postvaccination serologic testing among a large cohort of healthy adults.
    J Med Virol. 2022 May 10. doi: 10.1002/jmv.27848.
    PubMed     Abstract available


    April 2022
  135. KHAN YH, Mallhi TH, Alanazi AS, Butt MH, et al
    Outbreak of Acute Hepatitis of Unknown etiology in Children; The Critical Role of Healthcare Professionals in Neutralizing Misleading Narratives during the COVID-19 Pandemic.
    J Med Virol. 2022 Apr 29. doi: 10.1002/jmv.27819.
    PubMed    


  136. ZHANG C, Liu Y, Li J, Liu H, et al
    Dose-response relationship between qAnti-HBc and liver inflammation in chronic hepatitis B with normal or mildly elevated ALT based on liver biopsy.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27779.
    PubMed     Abstract available


  137. ZHAO D, Yu S, Guo P, Zhang X, et al
    Identification of potential plasma markers for hepatitis B virus-related chronic hepatitis and liver fibrosis/cirrhosis.
    J Med Virol. 2022 Apr 5. doi: 10.1002/jmv.27761.
    PubMed     Abstract available


    March 2022
  138. LIN P, Wen DY, Pang JS, Liao W, et al
    Proteomics profiling of nontumor liver tissues identifies prognostic biomarkers in hepatitis B-related hepatocellular carcinoma.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27732.
    PubMed     Abstract available


  139. YU J, Shi X, Yu H, Wu J, et al
    Impact of hepatitis-B-surface-antigen-positive grafts on liver transplantation in patients with benign and malignant liver disease.
    J Med Virol. 2022 Mar 7. doi: 10.1002/jmv.27703.
    PubMed     Abstract available


    February 2022
  140. WU J, Xu Y, Cui Y, Bortolanza M, et al
    Dynamic changes of serum metabolites associated with infection and severity of patients with acute hepatitis E infection.
    J Med Virol. 2022 Feb 23. doi: 10.1002/jmv.27669.
    PubMed     Abstract available


  141. JACKSON K, Holgate T, Tekoaua R, Nicholson S, et al
    Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing.
    J Med Virol. 2022;94:642-648.
    PubMed     Abstract available


    January 2022
  142. MOREIRA LVL, Malheiros AP, Barbosa KMV, Freitas PEB, et al
    The first evidence of Hepatitis A virus subgenotype IIIA in the Eastern Brazilian Amazon, 1982-1983.
    J Med Virol. 2022 Jan 25. doi: 10.1002/jmv.27625.
    PubMed     Abstract available


  143. LUO M, Chen Z, Liu M, Liang Q, et al
    Inhibitory Activities of Ranunculus japonicus Thunb. Ethanol Extract against Hepatitis B Virus.
    J Med Virol. 2022 Jan 24. doi: 10.1002/jmv.27621.
    PubMed     Abstract available


  144. LEON FJF, Silva LLD, Santos AC, Duarte da Costa V, et al
    Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus.
    J Med Virol. 2022 Jan 22. doi: 10.1002/jmv.27614.
    PubMed     Abstract available


  145. YU K, Mei Y, Wang Z, Liu B, et al
    LncRNA LINC00924 upregulates NDRG2 to inhibit epithelial-mesenchymal transition via sponging miR-6755-5p in hepatitis B virus-related hepatocellular carcinoma.
    J Med Virol. 2022 Jan 8. doi: 10.1002/jmv.27578.
    PubMed     Abstract available


    December 2021
  146. XIE Y, Ma H, Feng B, Song G, et al
    Combining the HBcrAg decline and HBV mutations predicts spontaneous HBeAg seroconversion in chronic hepatitis B patients during the immune clearance phase.
    J Med Virol. 2021 Dec 24. doi: 10.1002/jmv.27545.
    PubMed     Abstract available


  147. DENG H, Feng Q, Wu Y, Lin H, et al
    Immune response to hepatitis B vaccination in human immunodeficiency virus-positive patients in China: A 2-year retrospective study.
    J Med Virol. 2021 Dec 14. doi: 10.1002/jmv.27523.
    PubMed     Abstract available


    November 2021
  148. BOLINA-SANTOS E, Chaves DG, da Silva-Malta MCF, Carmo RA, et al
    HCV infection in hemophilia A patients is associated with altered cytokines and chemokines profile and might modulate the levels of FVIII inhibitor.
    J Med Virol. 2021 Nov 5. doi: 10.1002/jmv.27432.
    PubMed     Abstract available


  149. ZHENG S, Li M, Pan X, Huang X, et al
    Association of IL-32 rs28372698 polymorphism with active chronic HBV infection.
    J Med Virol. 2021;93:6236-6240.
    PubMed     Abstract available


    October 2021
  150. JI Q, Chu X, Zhou Y, Liu X, et al
    Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.
    J Med Virol. 2021 Oct 2. doi: 10.1002/jmv.27374.
    PubMed     Abstract available


    September 2021
  151. WU J, Bortolanza M, Zhai G, Shang A, et al
    Gut Microbiota Dysbiosis Associated with Plasma Levels of Interferon-gamma and Viral Load in Patients with Acute Hepatitis E Infection.
    J Med Virol. 2021 Sep 22. doi: 10.1002/jmv.27356.
    PubMed     Abstract available


  152. KAZMI SK, Khan FMA, Natoli V, Hunain R, et al
    Viral hepatitis amidst COVID-19 in Africa: Implications and Recommendations.
    J Med Virol. 2021 Sep 10. doi: 10.1002/jmv.27330.
    PubMed     Abstract available


  153. NICOLINI LA, Menzaghi B, Molteni C, Vichi F, et al
    Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C".
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27329.
    PubMed    


  154. YAO K, Wang J, Wang L, Xia J, et al
    Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus infected patients with normal ALT and detectable HBV DNA.
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27327.
    PubMed     Abstract available


    August 2021
  155. TARAFDAR S, Virata ML, Yan H, Zhong L, et al
    Multiple Epitopes of Hepatitis B Virus Surface Antigen Targeted by Human Plasma-derived Immunoglobulins Coincide with Clinically Observed Escape Mutations.
    J Med Virol. 2021 Aug 18. doi: 10.1002/jmv.27278.
    PubMed     Abstract available


  156. YAO Y, Shen Y, Shao H, Liu Y, et al
    Polymorphisms of RIG-I-like receptor influence HBV clearance in Chinese Han population.
    J Med Virol. 2021;93:4957-4965.
    PubMed     Abstract available


    July 2021
  157. WEI MT, Le MH, Landis C, Trinh H, et al
    Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C.
    J Med Virol. 2021 Jul 5. doi: 10.1002/jmv.27168.
    PubMed     Abstract available


    June 2021
  158. LEUMI S, El Kassas M, Zhong J
    Hepatitis C virus-genotype 4: a poorly characterized endemic genotype.
    J Med Virol. 2021 Jun 29. doi: 10.1002/jmv.27165.
    PubMed     Abstract available


  159. TADA T, Kurosaki M, Nakamura S, Hasebe C, et al
    Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27157.
    PubMed     Abstract available


  160. JI H, Chen S, He Q, Wang W, et al
    The different replication between nonenveloped and quasi-enveloped hepatitis E virus.
    J Med Virol. 2021 Jun 2. doi: 10.1002/jmv.27121.
    PubMed     Abstract available


  161. WANG Y, Li X, Chen Q, Jiao F, et al
    The relationship between liver pathological inflammation degree and pyroptosis in chronic hepatitis B patients.
    J Med Virol. 2021 Jun 1. doi: 10.1002/jmv.27114.
    PubMed     Abstract available


  162. SAJJAD M, Ali S, Baig S, Sharafat S, et al
    HBV S antigen evolution in the backdrop of HDV infection affects epitope processing and presentation.
    J Med Virol. 2021;93:3714-3729.
    PubMed     Abstract available


  163. JACKSON K, Tekoaua R, Li X, Locarnini S, et al
    Real-world application of the Xpert(R) HBV viral load assay on serum and dried blood spots.
    J Med Virol. 2021;93:3707-3713.
    PubMed     Abstract available


    April 2021
  164. XU Z, Lin JZ, Zeng YF, Yang XH, et al
    Changes of cytokine levels and T cell surface molecules in patients with chronic hepatitis B and the association with functional cure.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27041.
    PubMed     Abstract available


  165. BULFONI M, Pravisani R, Dalla E, Cesselli D, et al
    miRNA expression profiles in liver grafts of HCV and HIV/HCV infected recipients, six months after liver transplantation.
    J Med Virol. 2021 Apr 5. doi: 10.1002/jmv.26999.
    PubMed     Abstract available


    April 2019
  166. EL KASSAS M, Alboraie M, Omar H, El Latif YA, et al
    High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results.
    J Med Virol. 2019 Apr 5. doi: 10.1002/jmv.25478.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.